Differentiated pipeline established through our proprietary engine

Synedgen is well-positioned to lead the industry in the advancement of modified polysaccharides for therapeutic use. We are aggressively moving toward the clinic with numerous programs in the research or pre-clinical development stages.

Improving lives by changing the progression of disease

Our pipeline includes compounds with the potential to change the progression of disease in the following ways:

  • Address complications in cystic fibrosis that currently have limited treatment options.
  • Reduce damage and inflammation due to chemical, radiological or physical damage.
  • Disrupt biofilms and loosen mucus in the lungs and GI tract.
  • Target the host-pathogen interface utilizing novel mechanisms to reduce the challenge of antibiotic resistance.

Learn more about our lead program focused on cystic fibrosis